How cells manage their own proteins outside their walls
Misfolded proteins are among the leading drivers of age-related diseases, from Alzheimer's to Parkinson's. We know more and more about how cells tackle this problem on the inside. But what about the proteins outside the cell? A new review in Science is the first to systematically describe how "extracellular proteostasis" works -- and why it breaks down as we age.
Proteostasis is the cell's ability to keep its proteins in the right shape. That covers everything from production and folding to quality control and degradation. Inside the cell, the systems responsible are well mapped: chaperones help proteins fold correctly, the proteasome breaks down damaged proteins, and autophagy clears away larger aggregates. The space outside the cell -- the extracellular environment -- plays by different rules and relies on different players. A quality-control system exists there too, but until now it has been treated as a collection of isolated parts.
A network, not a pile of loose pieces
The review in Science argues that extracellular proteostasis is an organised network with three main components: extracellular chaperones that intercept proteins before they can aggregate, clearance mechanisms that ferry misfolded proteins to the liver or other organs for degradation, and signalling pathways that alert the cell when something goes wrong beyond its walls. Together, these elements form a system comparable in complexity to the intracellular proteostasis machinery -- yet one that has received decades less scientific attention.
The implications for ageing and disease are immediate. The amyloid plaques of Alzheimer's are extracellular protein aggregates. Transthyretin amyloidosis, a heart disease far more common in older adults than long assumed, arises when a protein misfolds and deposits in the heart and nerves in the space outside cells. In both conditions, the extracellular clearance mechanisms fall short. With age, the capacity of this system declines: chaperones become less active and clearance routes become congested.
Therapeutic territory that remains largely unexplored
Framing extracellular proteostasis as an integrated system opens up new therapeutic directions. If specific links in the network can be strengthened -- by boosting chaperone activity or improving clearance routes, for example -- that could benefit a range of age-related diseases. Some of those directions are already being explored: small molecule activators of extracellular chaperones are in early development. But the field is still finding its feet. The Science publication is less a breakthrough than a map of territory that researchers will spend the coming years building on.